What is the recommended dosing, monitoring, and management of Zilebesiran in adults with hypertension that remains uncontrolled despite maximally tolerated standard antihypertensive therapy?

Zilebesiran for Uncontrolled Hypertension

Zilebesiran is not currently recommended for routine clinical use in hypertension management, as it remains investigational and lacks cardiovascular outcomes trial data required for guideline endorsement. 1

Current Regulatory and Guideline Status

• Zilebesiran is an investigational RNA interference therapeutic that inhibits hepatic angiotensinogen synthesis, with a single subcutaneous dose reducing 24-hour blood pressure over approximately 6 months. 1

• The 2024 ESC Guidelines explicitly classify zilebesiran among "new therapies with blood pressure-lowering properties that await supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension." 1

• No FDA approval exists for zilebesiran as a standalone antihypertensive agent—the drug label information provided 2 appears to reference benazepril/hydrochlorothiazide combination therapy, not zilebesiran itself.

Clinical Trial Evidence (For Context Only)

While not yet guideline-endorsed, the investigational data shows:

Efficacy Data

• KARDIA-2 trial demonstrated significant blood pressure reductions when zilebesiran 600 mg was added to standard therapy: -12.1 mmHg with indapamide (95% CI -16.5 to -7.6), -9.7 mmHg with amlodipine (95% CI -12.9 to -6.6), and -4.5 mmHg with olmesartan (95% CI -8.2 to -0.8) at 3 months. 3

• Meta-analysis of available trials showed pooled 24-hour systolic blood pressure reduction of -12.84 mmHg (95% CI -16.00 to -9.68) compared to placebo. 4

• Effects persist for up to 24 weeks after a single subcutaneous injection, with doses of 300-600 mg producing reductions exceeding 15 mmHg at 3 months. 5

Safety Profile

• Adverse events were more common with zilebesiran than placebo: hyperkalemia (5.5% vs 1.8%), hypotension (4.3% vs 2.1%), and acute kidney failure (4.9% vs 1.5%), though most episodes were mild and resolved without intervention. 3

• Common side effects include injection-site reactions (pain, erythema) and headache. 6

• No serious hypotension or renal impairment directly attributable to RAAS suppression has been observed in short-term studies. 7

Recommended Management for Uncontrolled Hypertension (Current Standard)

Since zilebesiran is not available for clinical use, patients with uncontrolled hypertension on maximally tolerated therapy should follow established guidelines:

Escalation Strategy

• If blood pressure remains uncontrolled on two-drug combination therapy, escalate to three-drug combination: RAS blocker (ACE inhibitor or ARB) + dihydropyridine calcium channel blocker + thiazide/thiazide-like diuretic, preferably as a single-pill combination. 1

• Target systolic blood pressure of 120-129 mmHg in most adults, provided treatment is well tolerated. 1

• If the 120-129 mmHg target cannot be achieved due to poor tolerance, apply the "as low as reasonably achievable" (ALARA) principle. 1

Fourth-Line Options

• Consider adding spironolactone or other mineralocorticoid receptor antagonists for resistant hypertension (blood pressure uncontrolled on three-drug regimen including a diuretic). 1

• Novel aldosterone synthase inhibitors (baxdrostat, lorundrostat) and dual endothelin receptor antagonist aprocitentan have shown promise in phase 2-3 trials for resistant hypertension but similarly await outcomes data. 1

Critical Caveats

• The absence of cardiovascular outcomes data is the primary barrier to zilebesiran's clinical adoption—blood pressure reduction alone does not guarantee improved morbidity and mortality without dedicated outcomes trials. 1

• The KARDIA-3 trial is currently evaluating zilebesiran's impact on major cardiovascular outcomes in a larger global population. 5

• Optimal dosing appears to be between 250-500 mg based on meta-analysis, though 600 mg was used in KARDIA-2. 4

Future Considerations

• Zilebesiran may eventually offer advantages for patients with resistant hypertension, high cardiovascular risk, or adherence challenges with daily oral medications due to its prolonged duration of action. 5, 7

• Potential benefits beyond blood pressure reduction include target organ protection (heart, kidneys, retina), though this requires confirmation in long-term studies. 5

• Further research is needed to establish long-term safety, efficacy across diverse populations (current trials predominantly enrolled white participants), and integration into personalized hypertension management strategies. 6